Sosei Heptares - Investor and Press Conference on Today’s Announcement Regarding the Acquisition and License Transaction with Idorsia Jul 20, 2023 02:31AM
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company Jul 20, 2023 02:30AM
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia Jul 2, 2023 08:23PM
Sosei Heptares Provides Update on Lotiglipron Development Jun 26, 2023 06:40PM
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023 May 12, 2023 02:30AM
View Older Stories

Aug 12, 2021 03:00AM Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half 2021
Jul 6, 2021 03:00AM Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
May 19, 2021 03:00AM Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Mar 11, 2021 04:00AM Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
Feb 12, 2021 03:00AM Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020
Feb 1, 2021 02:00AM Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences
Jan 12, 2021 03:00AM Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target
Jan 5, 2021 02:00AM Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Dec 22, 2020 03:00AM Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
Dec 20, 2020 07:01PM Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
Dec 1, 2020 03:05AM Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Nov 20, 2020 04:05AM Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
Nov 11, 2020 02:55AM Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020
Sep 28, 2020 03:25AM Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials
Sep 3, 2020 04:57AM Sosei Heptares Appoints Top-Ranked Investment Analyst Hironoshin Nomura as Senior Vice President, Investor Relations and Corporate Strategy
Aug 13, 2020 03:52AM Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020
Jul 16, 2020 02:47AM Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds
Jun 5, 2020 03:18AM Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma
May 13, 2020 03:43AM Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020
May 7, 2020 04:00AM Sosei Heptares Announces Further Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia
May 1, 2020 02:48AM Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
Apr 14, 2020 04:00AM Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program
Mar 25, 2020 05:00AM Sosei Heptares Announces New Board Director Appointment and Executive Promotion
Mar 20, 2020 05:00AM Sosei Heptares Announces New Publication Highlighting the Potential of Structure-based Approaches to Generate Novel Peptide-based Drugs Targeting GPCRs
Feb 13, 2020 02:14AM Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months Ended 31 December 2019
Jan 13, 2020 07:05PM Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi
Dec 23, 2019 03:00AM Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer
Nov 28, 2019 04:02AM Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China
Nov 12, 2019 03:00AM Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019
Aug 13, 2019 03:06AM Sosei Heptares Operational Highlights and Consolidated Results for the First Half of FY2019
Aug 5, 2019 02:30AM Sosei Heptares and Takeda Enter Into New Strategic Multi-target Research, Development and Commercialization Partnership
Jul 16, 2019 02:30AM Sosei Heptares Enters Into Multi-target Research Collaboration and License Agreement With Genentech
Jun 10, 2019 03:00AM Sosei Heptares to Receive New $3 Million Milestone Payment from Pfizer, as It Advances a Second Candidate from the GPCR Collaboration for Clinical Development
May 23, 2019 07:46PM Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency
May 22, 2019 09:55AM Sosei Heptares Notes New Positive Phase II Data for QVM149, a Potential Novel Inhaled Combination for Treating Asthma, Were Presented at ATS 2019
Feb 20, 2019 01:52AM Sosei Heptares Starts New Clinical Development Program
Feb 4, 2019 02:41AM Sosei Heptares Announces Medicxi to Invest Up To €40 Million in New Collaboration Based on its Orexin Agonist Program
View Older Stories